| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2007-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55d53001f05e10be6b8d7740e156e5eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f5babe5e93d6b06874a3d5c86ca9b96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0860f5eb501e8d0e390706da46fc4a68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_675834a587871853495ae50e2e720293
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_598d7c8934bf4ba940c7db928c9835dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_705f91cfb0809452620d7d7e1345f125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6301774a25d12c72cdd0e817e441dfb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad92d834374c71e1fbeec9f628ba7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a63b66edc37536718c7f60e000e8b23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b81120a8a100dfdd0b4d1a9a643ab9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c162027a4315ae8ba86d65f8a177f99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_561451f32af100dce98140f6c55ea5fd |
| publicationDate |
2009-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2372089-C2 |
| titleOfInvention |
Method of treating patients suffering from colorectal cancer with liver metastases |
| abstract |
FIELD: medicine. n SUBSTANCE: invention concerns medicine, namely oncology and can be used in treatment of patients with colorectal cancer with multiple liver metastases. The first stage of treatment involves neoadjuvant oxalyplatine chemotherapy; in addition Tomudex is introduced in a dose 3 mg/m 2 as a 24 hour continuous infusion. After termination of chemotherapy, biotherapy involves intra-arterial injection of Avastin in a dose 10 mg/kg of body weight within 2 hours, neoadjuvant intra-arterial chemotherapy and biotherapy totals in 4-6 courses. At the second stage 4 weeks after chemotherapy surgery is performed. The third stage involves 4-6 courses of adjuvant intra-arterial chemotherapy and biotherapy, as at the first stage. n EFFECT: invention allows increasing survival rate and life expectancy of the patients owing to improved respectability of metastases and lower toxicity of complex neoadjuvant and adjuvant intra-arterial chemotherapy and biotherapy. n 1 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2760174-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2489150-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764955-C1 |
| priorityDate |
2007-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |